Inventor · disambiguated record
Amale Hawi
Also filed as: HAWI AMALE · HAWI AMALE A
5 granted patents·7 pending applications·31 citations·filing 1988–2023
76Inventor score
Files withTREVI THERAPEUTICS INC6BOEHRINGER INGELHEIM PHARMA2UNIV KENTUCKY RES FOUND2HAWI AMALE1PENWEST PHARMACEUTICALS CO1
Top patents by PatentIndex Score
12 records- 0176US5032402A3-hydroxy-N-methylpyrrolidone and use as transdermal enhancerUNIV KENTUCKY RES FOUND·Filed 1990·Granted Jul 16, 1991·20 cites·3 claims
- 0275US2023338367A1Treatment of prurigo nodularisTREVI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0367US2022347171A1Treatment of prurigo nodularisTREVI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0460US6255481B1Pharmaceutical suspension comprising nevirapine hemihydrateBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jul 3, 2001·1 cites·3 claims
- 0560US2018125840A1Treatment of prurigo nodularisTREVI THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 0646US9624233B2Compounds for treating pruritic conditionsTREVI THERAPEUTICS INC·Filed 2016·Granted Apr 18, 2017·0 cites·26 claims
- 0743US6172059B1Pharmaceutical suspension comprising nevirapine hemihydrateBOEHRINGER INGELHEIM PHARMA·Filed 1998·Granted Jan 9, 2001·5 cites·2 claims
- 0843US2020016150A1Treatment of the pruritic symptoms of liver diseaseTREVI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 0942US2018008592A1Treatment of uremic pruritusTREVI THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1040US2012101169A1Methods of providing anticoagulation effects in subjectsHAWI AMALE·Filed 2011·Application pending·0 cites
- 1134US4973708A3-hydroxy-N-methylpyrrolidone and preparation thereofUNIV KENTUCKY RES FOUND·Filed 1988·Granted Nov 27, 1990·5 cites·8 claims
- 1226US2011263720A1Synthesis of alpha-tocopherolquinone derivatives, and methods of using the samePENWEST PHARMACEUTICALS CO·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Amale Hawi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →